Format

Send to

Choose Destination
Pharm Res. 1999 Dec;16(12):1883-7.

An integrated model for determining causes of poor oral drug absorption.

Author information

1
Glaxo Wellcome, Inc., Research Triangle Park, North Carolina 27709, USA. yul@cder.fda.gov

Abstract

PURPOSE:

To develop an integrated absorption model for estimating the fraction of dose absorbed and determining the causes of poor oral drug absorption.

METHODS:

Both analytical and numerical methods were used to estimate the fraction of dose absorbed.

RESULTS:

An integrated absorption model was developed by considering transit flow, dissolution, and permeation processes, simultaneously. A framework was proposed to determine permeability-, dissolution-, and solubility-limited absorption. Digoxin, griseofulvin, and panadiplon were employed to illustrate the applications of the integrated model in identifying the causes of poor absorption and guiding formulation development.

CONCLUSIONS:

The integrated absorption model was successfully applied to digoxin, griseofulvin, and panadiplon to estimate the fraction dose absorbed and to roughly determine the causes of poor oral drug absorption.

PMID:
10644078
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center